Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Clinical trial NCT06893783 · RECRUITING

Trial details

NCT number: NCT06893783
Sponsor: Inkeun Park
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Carcinomas (NEC)Neuroendocrine Carcinoma of Pancreas Neuroendocrine Carcinoma of Prostate

Start date: 2025-09-02
Primary completion: 2029-04-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.